U
Usha Perepu
Researcher at University of Iowa
Publications - 14
Citations - 653
Usha Perepu is an academic researcher from University of Iowa. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 6, co-authored 10 publications receiving 308 citations.
Papers
More filters
Journal ArticleDOI
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Robert D. McBane,Waldemar E. Wysokinski,Jennifer Le-Rademacher,Tyler Zemla,Aneel A. Ashrani,Alfonso Tafur,Usha Perepu,Daniel M. Anderson,Krishna Gundabolu,Charles Kuzma,Juliana Perez Botero,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Damon E. Houghton,Prakash Vishnu,Charles L. Loprinzi +16 more
TL;DR: Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE) and apixaban is approved for the treatment of acute VTE.
Journal ArticleDOI
Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration.
Tobias Tritschler,Tobias Tritschler,Marie Eve Mathieu,Leslie Skeith,Marc A. Rodger,Saskia Middeldorp,Timothy A. Brighton,Per Morten Sandset,Susan R. Kahn,Susan R. Kahn,Derek C. Angus,Marc Blondon,Marc J. M. Bonten,Marco Cattaneo,Mary Cushman,Lennie P. G. Derde,Maria T. DeSancho,Jean Luc Diehl,Ewan C. Goligher,Ewan C. Goligher,Bernd Jilma,Peter Jüni,Peter Jüni,Patrick R. Lawler,Patrick R. Lawler,Marco Marietta,John C. Marshall,Colin McArthur,Carlos Henrique Miranda,Tristan Mirault,Nuccia Morici,Usha Perepu,Christian Schörgenhofer,Michelle Sholzberg,Alex C. Spyropoulos,Steve Webb,Ryan Zarychanski,Stéphane Zuily,Grégoire Le Gal +38 more
TL;DR: There is equipoise regarding the optimal dose of anticoagulant intervention in hospitalized patients with COVID‐19 and consequently, immediate answers from high‐quality randomized trials are needed.
Journal ArticleDOI
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
Usha Perepu,Isaac Matthew Chambers,Abdul Wahab,Patrick Ten Eyck,Chaorong Wu,Sanjana Dayal,Grerk Sutamtewagul,Steven R. Bailey,Lori J. Rosenstein,Steven R. Lentz +9 more
TL;DR: In this article, a randomized controlled trial comparing standard prophylactic dose versus intermediate dose enoxaparin in adults who were hospitalized with COVID-19 and admitted to an intensive care unit (ICU) and/or had laboratory evidence of coagulopathy was conducted.
Journal ArticleDOI
Standard Prophylactic Versus Intermediate Dose Enoxaparin in Adults with Severe COVID-19: A Multi-Center, Open-Label, Randomised Controlled Trial
Usha Perepu,Isaac Chambers,Abdul Wahab,Patrick Ten Eyck,Chaorong Wu,Sanjana Dayal,Grerk Sutamtewagul,Steven R. Bailey,Lori J. Rosenstein,Steven R. Lentz +9 more
TL;DR: In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not differ significantly in preventing death or thrombosis at 30 days.
Journal ArticleDOI
Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial
Robert D. McBane,Waldemar E. Wysokinski,Jennifer Le-Rademacher,Aneel A. Ashrani,Alfonso Tafur,Krishna Gundabolu,Juliana Perez-Botero,Usha Perepu,Daniel M. Anderson,Charles Kuzma,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Charles L. Loprinzi +13 more
TL;DR: Oral apixaban therapy was associated with very low rates of bleeding and significantly lower VTE recurrence with superior quality of life outcome measures compared to parenteral dalteparin in the treatment of cancer associated VTE.